Just two weeks ago, Merck KGaA and Pfizer were hit with a major setback for their PD-L1 immunotherapy, Bavencio, after it registered a major miss in lung cancer. Now, it has finally received some good news following the recommendation from NICE for its use in metastatic Merkel cell carcinoma (mMCC), with it receiving funding from the Cancer Drug Fund (CDF).
Original Article: Merck/Pfizer’s Bavencio wins slight reprieve after NICE nod